Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer

Published:2021-06 Issue:3 Volume:21 Page:e150-e153
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Bose Sminu^ORCID,Kalinsky Kevin

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study;Setiawan;Am J Epidemiol,2009

2. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).†;Cardoso;Ann Oncol,2018

3. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer;Araki;Breast Cancer,2018

4. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer;Creighton;Breast Cancer Res,2010

5. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance;Campbell;J Biol Chem,2001

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancer;G3 Genes|Genomes|Genetics;2023-03-06

2. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment;International Journal of Molecular Sciences;2023-01-24

3. A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancer;2022-09-25

4. Antineoplastics;Reactions Weekly;2022-01

5. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition;npj Precision Oncology;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3